Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity

• US 5,736,576 A
• Filed: 06/04/1996
• Issued: 04/07/1998
• Est. Priority Date: 06/04/1996
• Status: Expired due to Term

• Current Assignee: Octamer, Inc.
• Original Assignee: Octamer, Inc.
• Inventors: Mendeleyev, Jerome, Kun, Ernest
• Primary Examiner(s): CHANG, CELIA C
• Application Number:
  US08/655,267
• Time in Patent Office: 672 Days
• Field of Search: 514/568, 514/570, 560/59, 560/60, 560/61, 560/62
• US Class Current: 514/570
• CPC Class Codes: A61K 31/166 having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/235 having an aromatic ring attached to a carboxyl group
• CPC Class Codes: C07C 69/92 with etherified hydroxyl groups

Abstract

The present invention provides methods for treating cancer, particularly malignant tumors, with thyroxine analogues having no significant hormonal activity. A thyroxine analogue is administered to an afflicted mammal in an amount effective to cause depression or regression of malignant tumor growth or to treat cancer.

Claims

1. A method for treating a malignant tumor in a mammal comprising the step of administering an amount of methyl 3,5-diiodo-4-(4'"'"'-methoxyphenoxy) benzoate sufficient to depress growth of the malignant tumor.

2. The method of claim 1 wherein said malignant tumor is selected from the group consisting of melanoma, prostate cancer, cervical cancer, promyelocytic leukemia, mammary cancer, and ductal mammary cancer.

3. The method of claim 1 wherein said malignant tumor is selected from the group consisting of mammary cancer and ductal mammary cancer.